Loading...
•
Mar 31, 2022
Centessa Q1 2022 Earnings Report
Centessa Pharmaceuticals reported financial results for the first quarter ended March 31, 2022 and provided business updates.
Key Takeaways
Centessa Pharmaceuticals reported first quarter 2022 financial results, highlighting the advancement of its rare disease and immuno-oncology portfolio towards its '4x24' goal. The company's cash and cash equivalents were $544.5 million as of March 31, 2022, providing an operational cash runway to mid-2024.
Advanced innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024.
Poster presentation at ASCO 2022 to highlight LB101 preclinical data in solid tumors; IND planned for late 2022.
ZF874 for AATD Phase 1 update on track for 2H 2022; interim data from multiple dose cohorts with PiMZ and PiZZ subjects.
Cash and cash equivalents of $544.5 million as of March 31, 2022; Operational cash runway to mid-2024.
Centessa
Centessa
Forward Guidance
Centessa Pharmaceuticals expects to share data from the ongoing Phase 1 study of ZF874 in AATD in the second half of 2022, initiate a streamlined clinical program to support registration for SerpinPC for the treatment of Hemophilia B in the second half of 2022, and plans an IND for CBS004 in Autoimmune Diseases in late 2022.
Positive Outlook
- LB101 preclinical data will be presented at ASCO 2022 in June 2022.
- An IND for LB101 is planned for late 2022.
- ZF874 Phase 1 study data expected in the second half of 2022.
- SerpinPC clinical program to support registration for Hemophilia B is expected to initiate in the second half of 2022.
- CBS004 IND is planned for late 2022.